Business Context and Reporting Period
Propanc Biopharma, Inc. filed this Form 8-K on July 3, 2019, reporting the entry into a material definitive agreement. The Company is incorporated in Delaware and maintains its principal executive offices in Camberwell, Australia. Its common stock trades on the OTCQB market under the symbol PPCB.
Key Financial Metrics and Transaction Details
The filing details a financing transaction rather than periodic financial performance metrics such as revenue or operating margins. Key transaction figures include:
- Principal Amount: $78,000.00
- Net Proceeds: $75,000.00 (after fees)
- Transaction Fees: $3,000.00 paid to the lender
- Interest Rate: 8% per annum (payable in cash or shares)
- Default Interest Rate: 22% per annum
- Maturity Date: July 3, 2020
- Use of Proceeds: General working capital
Material Changes and Instrument Terms
The Company entered into a Securities Purchase Agreement with Power Up Lending Group Ltd. for a convertible promissory note. Material terms include:
- Conversion Rights: The note is convertible into common stock at the lender's option starting December 31, 2019. The conversion price is generally $5.00, subject to a variable adjustment based on the Market Price (average of lowest three closing bid prices over ten days). The price is capped at the greater of 65% of the Market Price or $3.05 if the Market Price is $\ge$ $5.00, and the lesser of the variable price or $3.05 if the Market Price is < $5.00.
- Conversion Limit: The lender cannot convert if it would result in beneficial ownership exceeding 4.99% of outstanding shares.
- Prepayment Penalties: Prepayment is allowed until 180 days from issuance but incurs significant premiums ranging from 110% to 129% of the face amount plus accrued interest, depending on the timing of prepayment.
- Default Provisions: Upon an event of default, the outstanding obligation increases to 150% of the principal plus accrued interest (the "Default Amount"). Events of default include failure to reserve shares, delisting, cessation of operations, or financial restatements.
Guidance, Risks, and Contingencies
The filing does not provide forward-looking guidance on revenue or earnings. However, it highlights specific risks and contingencies associated with the new debt:
- Liquidity Risk: The Company covenants not to dispose of substantially all assets without consent, which could restrict strategic flexibility.
- Dilution Risk: The variable conversion price mechanism and the 4.99% beneficial ownership cap may lead to significant dilution for existing shareholders upon conversion.
- Default Risk: The high default interest rate (22%) and the 150% default penalty create substantial financial liability if the Company fails to meet covenants or payment obligations.
- Reporting Risk: Failure to meet reporting obligations under the Exchange Act constitutes an event of default.
Investor Verification Checklist
- Verify the current Market Price of PPCB to calculate the potential conversion price and dilution impact.
- Confirm the Company's ability to reserve the required number of shares (at least five times the issuable amount) as mandated by the note.
- Review the Company's cash position to assess its ability to service the 8% interest or prepay the note without incurring the 110-129% penalties.
- Check for any subsequent filings regarding the status of the note or additional debt obligations.